ALTASCIENCES
WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.
The expansion added 5,000 square feet of configurable clinical trial facilities. This further ensures participants have access to a socially distanced, comfortable space in which to complete study procedures. An additional 700 square feet of lab space was also added. Read the original press release .
“We are thrilled to be able to provide more functional space for our study participants and staff, and create a dosing environment that can support blinded administrations of medications. This expansion increases unit capacity, operational efficiency, and freedom of movement. We look forward to showcasing our brand-new expansion to our clients and for our subjects to have added comfort during their participation at our site ,” said Dr. David Nguyen, Chief Medical and Operations Officer at WCCT Global, an Altasciences company.
Chris Perkin, CEO of Altasciences, adds, “The dosing of the first participants in our West Coast clinic expansion is an important milestone in the evolution of our clinical trial offerings, for both long-term stays and outpatient visits. We are excited to see it come to fruition, and contribute to Altasciences’ continued growth to support early-stage drug development .”
Altasciences acquired WCCT Global on February 12, 2021, adding a third clinical location to existing facilities in Kansas City, U.S.A. and Montreal, Canada. Read the acquisition press release .
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider platformen med tilføjelsen af Liberty IT Consulting Group fra Australien21.8.2025 18:12:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine digitale transformationskompetencer yderligere med Liberty IT, der er en førende leverandør af digital transformation i virksomhedsklassen inden for finansielle services. Liberty IT, der blev grundlagt i 2016 og har hovedkontor i Australien, specialiserer sig i teknologirådgivning for førende finansielle organisationer såsom banker, formueforvaltere og børsen. Virksomheden er specialiseret inden for modernisering af banksystemer, betalingsløsninger, data og digitale løsninger med særligt fokus på implementering af cloudbaserede løsninger, systemintegration, datamigrering, programmering, DevOps, kunstig intelligens og fusioner og integrationer af virksomheder. Med et stærkt renomme på markedet samarbejder Liberty IT med kunder om at levere skalerbare platforme, øge driftsmæssig effektivitet, optimere ydeevne, reducere omkostninger, maksimere sandsynligheden for succesfuld projektlevering og accelerere digitale transformationsinitiativer. "Samarbejdet med
Veridas Identity Fraud Solutions Now Available on AWS Marketplace21.8.2025 18:05:00 CEST | Press release
Veridas, a global leader in identity verification and biometric solutions, today announced that its Identity Verification (IDV) platformis now available on Amazon Web Services (AWS) Marketplace. This launch puts the full power of Veridas’ fraud prevention and identity verification capabilities in the hands of millions of AWS customers worldwide, making secure digital trust only a click away. As identity fraud rises exponentially — with threats from synthetic identities, deepfakes, and injection attacks — Veridas delivers a cloud-native solution combining facial biometrics, AI-driven document authentication, and certified liveness detection. The platform shields enterprises from fraud while enabling seamless onboarding in seconds. “Live since 2017, our IDV platform already protects more than 300 clients in 25 countries against advanced fraud such as deepfakes and injection attacks, with 100% proprietary technology, global coverage, and international compliance,” said Eduardo Azanza, CEO
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™21.8.2025 17:21:00 CEST | Press release
Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud to be supporting Steel Therapeutics at this key stage of their development journey,” said Steve Mason, Co-COO at Altasciences. “Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.” Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach b
Media alert | Masdar receives ‘AA-’ credit rating with stable outlook by S&P Global Ratings in further recognition of the financial strength of the business21.8.2025 15:55:00 CEST | Press release
Masdar has been assigned an ‘AA-’ credit rating with a stable outlook by S&P Global Ratings, reinforcing its position as a global clean energy leader. This new rating reflects Masdar's diversified global position, strong growth prospects, and disciplined financial policies, including the allocation of green bond proceeds to finance the construction of new projects. With top credit ratings now secured from Moody’s (A1), Fitch (AA-) and S&P (AA-), Masdar continues to be recognized as one of the most financially robust renewable energy companies worldwide. This enables the Company to continue to drive responsible expansion and deliver inclusive progress across key international markets. The rating is also underpinned by the strong support of the Company's three shareholders - Abu Dhabi National Oil Company (ADNOC), Mubadala Investment Company, and Abu Dhabi National Energy Company PJSC (TAQA) - as well as the Government of Abu Dhabi. View source version on businesswire.com: https://www.bu
Verb Technology Announces $780 Million in Treasury Assets to Advance its TON Treasury Strategy21.8.2025 15:20:00 CEST | Press release
Verb Technology Company, Inc. (Nasdaq: VERB) (to be renamed Ton Strategy Company) (the “Company”) today announced treasury assets exceeding $780 million, including $713 million1 of Toncoin ($TON), the native cryptocurrency of The Open Network (“TON”) Blockchain, and $67 million of cash. This is an important milestone in the Company’s implementation of its previously announced $TON treasury strategy. Today’s news follows the Company’s August 8 closing of a $558 million private placement joined by more than 110 institutional and crypto-native investors. The Company used the majority of proceeds from the private placement to acquire $TON as its primary treasury reserve asset. "Crossing $780 million in assets just days after our private placement reflects the conviction behind $TON,” said Manuel Stotz, Executive Chairman of the Company. “This is more than building a balance sheet; it’s about contributing to the security of TON blockchain – where participants can build, transact, and benefi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom